California Biomedical Industry - California Healthcare Institute

More documents

Recommendations

Info

Larta Institute: Accelerating innovation from lab to marketLarta Institute is a leading “innovationhub” and commercialization servicesfirm based in Los Angeles and workingglobally to improve the transitionof scientific and technologicalbreakthroughs from the laboratoryto the marketplace. The instituteoffers a range of services for states,government agencies, and regionalpartners in innovation policy andconsultation, technology andcommercial assessments, and handsoncommercialization programs withentrepreneurs under sponsored clientprograms.The NIH Commercialization AssistanceProgram (NIH-CAP) is designedand managed by Larta Institute inpartnership and under contract withNIH. NIH-CAP is a 10 month mentoringand partnering-oriented effort geared toaccelerate the commercial and marketreadiness of award-winning life sciencecompanies supported by the variousNIH institutes across variety of healthcare areas. More on Larta Institute:www.larta.orgAdvanced Brain Monitoring, Inc.CarlsbadWebsite: http://www.b-alert.comPublic health issue:Obstructive Sleep Apnea (OSA) is oneof the world’s most prevalent, underdiagnosed disorders, responsible formore mortality and morbidity than anyother sleep disorder and recognizedas a major public health concern. OSAis characterized by recurrent failuresto breathe during sleep resulting fromobstruction of the upper airway. OSAcan cause daytime drowsiness andmemory impairment, and has beenassociated with hypertension, increasedrisk of cardiovascular disease, diabetesand stroke. Untreated OSA patients arethree to seven times more likely to beinvolved in industrial and motor vehicleaccidents due to slower reaction timesand impaired vigilance. Despite thisgrowing evidence that OSA threatenspublic health, safety and productivity,current estimates reveal that 93 percentof women and 82 percent of menwith moderate to severe OSA remainundiagnosed.Technology developed:The patented Apnea Risk EvaluationSystem (ARES) is an easy-to-apply,in-home system for diagnosing OSA.The ARES combines a miniaturized,battery-powered device to measureblood oxygen levels, pulse rate,snoring sounds, nasal pressure andhead position/movement with aquestionnaire to assess known riskfactors.The success story:ABM now holds six patents on thesetechnologies and the ARES was clearedby the FDA. Watermark Medical (WM)is now the exclusive distributor of ARESin the United States. Rotech Heathcare’sSleep Central has a national distributornetwork of sales reps selling the WMHome Sleep Testing turnkey homesolution for conducting sleep studies.NIH-CAP’s benefit to the company:With funding from the SBIR program,Advanced Brain Monitoring, Inc.is addressing sleep apnea, memorydysfunction, and alertness monitoringwith instrument systems that combinelaboratory level accuracy with theportability, ease of use and low costof consumer electronics. SBIR fundshave allowed ABM to completecomprehensive multi-site clinicaltrials to establish the validity of thetechnologies. These studies would bedifficult to fund with private sectorfinancing.SAM Technology, Inc.San FranciscoWebsite: http://www.eeg.comPublic health issue:SAM Technology developed IMAGEVUE to visualize and localize the originand spread of epileptic seizures in thehuman brain in planning neurosurgicaltreatment of complex partial seizuredisorders that are refractory totreatment with antiepileptic drugs.Technology developed:IMAGE VUE is a software system,running under Windows XP, for coregisteringelectroencephalography(EEGs) with magnetic resonanceimaging (MRIs), performing patentedDEBLURRING spatial enhancementand several types of source localizationanalysis, and interactive 3-D graphicsvisualization. The patented XCALIPERhardware and associated softwarefacilitates rapid measurement of EEGelectrode positions needed for coregistrationwith MRIs.The success story:IMAGE VUE is marketed toneurologists by Nicolet Biomedical,Inc., a subsidiary of VIASYS Healthcare,and the world’s largest supplier to theclinical neurology market. A number20 | California Biomedical Industry 2011 Report
of competing products worldwide weremodeled on IMAGE VUE platformtechnology.NIH-CAP’s benefit to the company:The SBIR program enableddevelopment of a first-of-its-kind,turnkey software package for animportant medical neurological nichemarket for which the economics didnot justify private sector investment.In the course of developing IMAGEVUE, SAM Technology gainedexperience in making an easy-to-usespecialized system, in developingsoftware in accordance with FDA GoodManufacturing Practices, in registeringa medical device with the FDA, and innegotiating an equitable distributoragreement with a company 100 timeslarger than itself.KeraMed Inc.SunnyvaleWebsite: htttp://www.keramed.comPublic health issue:There is only enough donor corneatissue to treat 1 percent of the 10 millionbilaterally cornea blind patients eachyear. Also, there was not a treatmentprocedure for cornea blindness in thethird world simple enough for noncornealspecialist eye surgeons toperform implantation.Technology developed:KeraMed developed a new type ofartificial cornea, called the KeraKlear,which can be used to treat corneablindness without the need for donorcorneal tissue. This artificial corneacan be implanted using an automatedrobotic device developed by thecompany or with a femtosecond laser.The first two patients who receivedthe implants had remarkably quickrecoveries as compared to standardtransplantation, which typicallyrequires about 12 months before goodvision is obtained. The first patient wasa 93 year old woman who had beenblind for 30 years from an alkali injuryand glaucoma. Before her surgeryshe could only see light, but after thesurgery she was able to read the largeletters on the eye chart and see thefaces of her family. The second patientwas even more remarkable. His visionimproved from only being able to seehand motions before surgery to beingable to read large print (20/80 vision)in one day.The success story:The KeraKlear has received EuropeanCE Mark approval. KeraMed iscurrently organizing a U.S. FDA 510kclinical study to enable use of theproduct in the U.S.NIH-CAP’s benefit to the company:The SBIR program gave KeraMed theseed funding to begin their artificialcornea project. Without SBIR fundingthey would not have been able todevelop the prototypes that proved thefeasibility of the technology.Wave 80 BioSciencesSan FranciscoWebsite:http://www.wave80.com/index.phpPublic health issue:There did not exist a high-performance,compact-form-factor system formeasurement of high-clinical-valuebiomarkers in peripheral blood.A molecular diagnostics systemwas needed to operate across thefull spectrum of environments ofclinical laboratory testing, rangingfrom sophisticated high-throughputlaboratories to small clinics in remoteareas to be applied to infectious disease,cancer, autoimmune disease, and otherhuman health conditions.Technology developed:Wave 80 develops moleculardiagnostic assays and handheld andbenchtop devices for infectious diseasemonitoring. In 2007, Wave 80 initiateda development program combiningnovel nucleic acid assay methods withfluid transport technology adapted fromintegrated circuit thermal managementto address emerging needs for viral loadmonitoring to accompany expandingaccess to antiretroviral therapy amongthe estimated 30 million people livingwith HIV in low- and middle-incomecountries. Wave 80 has developed ahandheld diagnostic device for malaria.It now is working on a more accuratetool to tell physicians if a baby born toan HIV-infected mother is also infectedwith the virus.The success story:In 2009, Wave 80 was awarded a$7.5 million contract by the NationalInstitute of Allergy and InfectiousDiseases, part of the National Institutesof Health, for rapid HIV/AIDS nucleicacid testing systems for use in lowresource settings. The duration of the2009 NIH contract is five years. Thefirst versions of the EOSCAPE-HIVsystem are scheduled to enter betatesting in clinics in Kenya and SouthAfrica in 2011.NIH-CAP’s benefit to the company:Wave 80 received funding for moleculardiagnostics research and developmentunder the Small Business InnovativeResearch program from both NIH, theNational Science Foundation, and theU.S. Department of Defense. Wave 80now has a multimillion dollar contractwith NIH.California Biomedical Industry 2011 Report | 21
Page 5 and 6: In analyzing California’s biomedi
Page 7 and 8: scans from patients a continent awa
Page 11 and 12: Figure 1: Distribution of employmen
Page 13 and 14: Figure 8: California biomedical ind
Page 15 and 16: state operations (Figure 16). For t
Page 17 and 18: FigureFigure20.14:VentureVenturecap
Page 19 and 20: Survey participants also rankedfede
Page 21: State tax credits to support the gr
Page 25 and 26: Sacramento area shows growth and pr
Page 27 and 28: Figure 38: California has largest c
Page 29 and 30: OncologyCancers in California, 2010
Page 31 and 32: Diagnostics advancementsNew ovarian
Page 33 and 34: Patient profileBill Walton striding
Page 35 and 36: families themselves; to institution
Page 37 and 38: HIV and AIDS statisticsby stateAn e
Page 39 and 40: Researcher profileDr. Samuel So add
Page 41 and 42: Immunology and inflammatory disorde
Page 43 and 44: Cardiovascular diseaseAs is the cas
Page 45 and 46: Diabetes and metabolic disordersPha
Page 47 and 48: Researcher profileFrancine R. Kaufm
Page 49 and 50: ___________________________________
Page 51 and 52: Figure 41. Since 2007 there has bee
Page 53 and 54: time that wireless technologies can
Page 55: Workforce developmentA thriving ent
Page 58 and 59: access and quality while addressing
Page 60 and 61: California State University SystemR
Page 62 and 63: StanfordSummer research program re-
Page 64 and 65: Bellush said that bringing BiotechA
Page 66 and 67: Amylin PharmaceuticalsSummer Intern
Page 68 and 69: Bringing Science to Life in OurScho
Page 70 and 71: the private sector. NIH funding ena
Page 72 and 73:
Small Business Administrationprogra
Page 74 and 75:
Promising UC research fundedby NIHB
Page 76 and 77:
University of Southern California
Page 78 and 79:
Stanford UniversitySince its foundi
Page 80 and 81:
The Scripps Research Institute (TSR
Page 82 and 83:
Sanford-Burnham Medical Research In
Page 85 and 86:
small biotechnology companies as th
Page 87 and 88:
The Salk Institute celebrates 50 ye
Page 89 and 90:
Bayer HealthCare establishes U.S.In
Page 91:
UC Merced: Addressing healthcare di
Page 95 and 96:
Executive profileDr. Ed Holmes, Pre
Page 97 and 98:
“Only by lowering the barriers to
Page 99 and 100:
Researcher profileHans Keirstead, P
Page 101 and 102:
Special sectionPharmaceuticals in t
Page 103 and 104:
MethodologyEmployment, Wages, andIn
Page 105:
NIH GrantsDataData for this analysi
Page 108:
Report authors hereDavid L. Gollahe
show all

California Biomedical Industry - California Healthcare Institute

Create successful ePaper yourself

Delete template?

Save as template?